CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments

Manasi P. Jogalekar, Ramya Lakshmi Rajendran, Fatima Khan, Crismita Dmello, Prakash Gangadaran*, Byeong Cheol Ahn*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell leukemia or lymphoma. Unfortunately, many challenges remain to be addressed to overcome its ineffectiveness in the treatment of other hematological and solidtumor malignancies. The major hurdles of CAR T-cell therapy are the associated severe life-threatening toxicities such as cytokine release syndrome and limited anti-tumor efficacy. In this review, we briefly discuss cancer immunotherapy and the genetic engineering of T cells and, In detail, the current innovations in CAR T-cell strategies to improve efficacy in treating solid tumors and hematologic malignancies. Furthermore, we also discuss the current challenges in CAR T-cell therapy and new CAR T-cell-derived nanovesicle therapy. Finally, strategies to overcome the current clinical challenges associated with CAR T-cell therapy are included as well.

Original languageEnglish (US)
Article number925985
JournalFrontiers in immunology
StatePublished - Jul 22 2022


  • CAR T-cell therapy
  • gene therapy
  • hematologic malignancies
  • immunotherapy
  • solid cancers

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments'. Together they form a unique fingerprint.

Cite this